Toledo Fabio Vieira, De Carli Daniel, Meletti Jose Fernando Amaral, Togo Herman Yuri Almeida, Gomes Italo Pires, Sakashita Renato Makoto, Montes Lucas Felix, Tiburcio Rafael Santos, Miranda Cesar de Araujo
Faculdade de Medicina de Jundiaí (FMJ), Departamento de Anestesiologia, Jundiaí, SP, Brazil.
Faculdade de Medicina de Jundiaí (FMJ), Departamento de Anestesiologia, Jundiaí, SP, Brazil.
Braz J Anesthesiol. 2025 May-Jun;75(3):844618. doi: 10.1016/j.bjane.2025.844618. Epub 2025 Apr 4.
Blood transfusions are associated with increased morbidity and mortality, and maintaining global blood supplies can be a challenge. This systematic review investigates the impact of preoperative iron supplementation on the risk of blood transfusion among non-anemic patients undergoing major surgeries.
We conducted a systematic search of PubMed, Embase, and Cochrane Central for randomized controlled trials published up to May 2024. Studies involving the use of erythropoietin, or patients already using iron supplementation when trial randomization was conducted were excluded. Outcomes assessed included the number of individuals who received blood transfusions, and mean hemoglobin levels at the first day and by the first postoperative week.
A total of 1,162 non-anemic patients from 9 studies were included. Of these, 54% received preoperative iron supplementation. The average age was 71 years, and 44% were women. Preoperative iron supplementation was associated with a significantly lower risk of receiving a blood transfusion (OR = 0.54; 95% CI 0.40 to 0.75; p < 0.001). At the first postoperative day, the iron supplementation group had significantly higher mean hemoglobin levels compared to the no-treatment group (MD = 0.22 g.dL; 95% CI 0.02 to 0.42; p = 0.03). However, the pooled results could not rule out the null hypothesis for the difference in mean hemoglobin levels throughout the first week (MD = 0.12 g.dL; 95% CI -0.12 to 0.35; p = 0.34).
Preoperative intravenous iron supplementation in non-anemic patients undergoing major surgeries, particularly cardiac procedures, significantly reduces transfusion requirements. However, the benefits of oral iron remain uncertain, and further research is warranted to establish standardized perioperative supplementation protocols.
CRD42024552559.
输血与发病率和死亡率的增加相关,维持全球血液供应可能是一项挑战。本系统评价调查术前补充铁剂对接受大手术的非贫血患者输血风险的影响。
我们对截至2024年5月发表的随机对照试验在PubMed、Embase和Cochrane Central进行了系统检索。排除涉及使用促红细胞生成素的研究,或在试验随机分组时已使用铁剂补充的患者。评估的结局包括接受输血的个体数量,以及术后第一天和术后第一周时的平均血红蛋白水平。
纳入了来自9项研究的共1162例非贫血患者。其中,54%接受了术前铁剂补充。平均年龄为71岁,44%为女性。术前补充铁剂与接受输血的风险显著降低相关(比值比=0.54;95%置信区间0.40至0.75;p<0.001)。术后第一天,铁剂补充组的平均血红蛋白水平显著高于未治疗组(平均差=0.22g/dL;95%置信区间0.02至0.42;p=0.03)。然而,汇总结果不能排除整个第一周平均血红蛋白水平差异的零假设(平均差=0.12g/dL;95%置信区间-0.12至0.35;p=0.34)。
在接受大手术尤其是心脏手术的非贫血患者中,术前静脉补充铁剂可显著降低输血需求。然而,口服铁剂的益处仍不确定,有必要进行进一步研究以建立标准化的围手术期补充方案。
CRD42024552559。